Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients With Primary Hypercholesterolemia.

NCT06747936 is registered in ClinicalTrials.gov with Addpharma Inc. as lead sponsor.

NCT NCT06747936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06747936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients With Primary Hypercholesterolemia.
Lead sponsor
Addpharma Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 3, 2025
Completion date
May 30, 2025
Enrollment
129 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary hypercholesterolemia